{"id":"NCT03319732","sponsor":"RVL Pharmaceuticals, Inc.","briefTitle":"A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS","officialTitle":"An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients With Spasticity (Study OS440-3005)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-03","primaryCompletion":"2020-01-27","completion":"2020-06-11","firstPosted":"2017-10-24","resultsPosted":"2022-07-15","lastUpdate":"2022-08-09"},"enrollment":323,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis","Spasticity, Muscle"],"interventions":[{"type":"DRUG","name":"Arbaclofen","otherNames":["AERT"]}],"arms":[{"label":"AERT 80 mg","type":"EXPERIMENTAL"}],"summary":"Spasticity is a common complication in MS and occurs in up to 84% of patients. The main sign of spasticity is resistance to passive limb movement characterized by increased resistance to stretching, clonus, and exaggerated deep reflexes. Osmotica Pharmaceutical is currently developing arbaclofen extended-release tablets (AERT) for the treatment of spasticity in patients with MS.","primaryOutcome":{"measure":"Number of Participants With Adverse Events, Change in Vital Signs, Clinical Laboratory Test Results, 12-lead ECGs, USP Questionnaire, and C-SSRS Results","timeFrame":"over 1 year","effectByArm":[{"arm":"AERT 80 mg","deltaMin":276,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["36861013"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":323},"commonTop":["Urinary Tract Disorder","Muscular Weakness","Nausea","Asthenia","Dizziness"]}}